Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Deferasirox
Drug ID BADD_D00594
Description Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Indications and Usage For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Marketing Status Prescription
ATC Code V03AC03
DrugBank ID DB01609
KEGG ID D03669
MeSH ID D000077588
PubChem ID 214348
TTD Drug ID D0Q5UQ
NDC Product Code 62332-412; 43598-856; 57664-769; 62332-411; 62756-569; 0078-0469; 70771-1411; 66039-871; 69097-550; 70771-1471; 72647-371; 62512-0078; 68462-494; 69539-021; 31722-012; 69097-391; 57664-770; 58032-2017; 69539-200; 63278-1070; 72647-372; 46708-324; 69452-159; 62332-410; 53104-7713; 72606-014; 11722-040; 69097-570; 43598-851; 62332-324; 67877-549; 69539-022; 66022-0301; 0591-3853; 45963-456; 14501-0049; 46708-410; 62332-325; 46708-879; 72606-013; 62756-570; 69238-1486; 43598-854; 65085-0063; 62332-326; 69238-1704; 70710-1011; 59285-010; 46708-326; 70710-1012; 59651-419; 16714-995; 69539-199; 72205-076; 65727-037; 74436-0323; 57664-768; 68462-495; 46708-325; 69452-160; 0078-0713; 65015-738; 16714-993; 69097-393; 69097-560; 0078-0470; 31722-013; 69539-074; 43598-853; 70700-269; 70771-1409; 49706-2103; 70710-1277; 43598-855; 0078-0468; 65372-1164; 16714-994; 43598-852; 45963-455; 46708-412; 0078-0727; 70771-1472; 72647-373; 68462-496; 67877-553; 69238-1703; 45963-454; 69452-161; 0078-0654; 62756-568; 70771-1473; 69539-023; 67877-550; 0078-0720; 70710-1275; 31722-011; 72606-015; 70771-1410; 69539-075; 67877-551; 70710-1013; 67877-554; 72205-075; 0078-0656; 70700-270; 69238-1702; 0078-0655; 46708-411; 69097-392; 69539-073; 69238-1487; 67877-552; 70700-271; 70710-1276; 69238-1488
Synonyms Deferasirox | 4-(3,5-Bis-(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl)benzoic acid | ICL 670A | ICL-670A | ICL670A | ICL-670 | ICL670 | ICL 670 | Exjade
Chemical Information
Molecular Formula C21H15N3O4
CAS Registry Number 201530-41-8
SMILES C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Drug hypersensitivity10.01.01.001--Not Available
Dry eye06.08.02.001--
Dry mouth07.06.01.002--
Dry skin23.03.03.001--
Duodenal ulcer07.04.02.0020.026240%
Duodenal ulcer haemorrhage24.07.02.020; 07.04.02.0040.014578%Not Available
Duodenal ulcer perforation07.04.02.0030.003803%Not Available
Duodenitis07.08.03.0010.005831%Not Available
Dysarthria17.02.08.001; 19.19.03.001--
Dysgeusia17.02.07.003; 07.14.03.001--
Dysmenorrhoea21.01.01.0020.005831%
Dyspepsia07.01.02.0010.072890%
Dysphagia07.01.06.003--
Dysphonia22.02.05.005; 19.19.03.002; 17.02.08.004--
Dyspnoea02.01.03.002; 22.02.01.004--
Dyspnoea exertional22.02.01.005; 02.01.03.003--Not Available
Dysuria20.02.02.0020.032071%
Ear disorder04.03.01.0010.005831%Not Available
Ear infection11.01.05.001; 04.03.01.006--Not Available
Ear pain04.03.01.0030.005831%
Eating disorder19.09.01.008; 14.03.01.0080.026240%Not Available
Ecchymosis24.07.06.002; 23.06.01.001; 01.01.03.0010.005831%Not Available
Eczema23.03.04.006--
Electrolyte depletion14.05.01.0010.005831%Not Available
Electrolyte imbalance14.05.01.0020.020409%Not Available
Encephalitis17.06.05.001; 11.01.03.0080.005831%
Encephalopathy17.13.02.0010.023325%
Endocarditis11.01.16.001; 02.09.01.0010.001521%
Enuresis20.02.02.003; 19.07.04.0010.005831%Not Available
Eosinophil count decreased13.01.06.0030.005831%Not Available
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 28 Pages